XML 48 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative Research and License Agreements (Details)
 3 Months Ended 6 Months Ended
Nov. 13, 2019
USD ($)
agreement
Feb. 17, 2019
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Collaboration revenue     $ 79,000 $ 4,847,000 $ 1,076,000 $ 14,030,000    
Deferred revenue, current     7,267,000   7,267,000   $ 8,343,000  
AbbVie Collaboration | Collaboration Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of collaboration programs | agreement 2              
Non-refundable upfront payment received for research agreement $ 25,000,000              
Collaboration option exercise fee 10,000,000              
Collaboration option exercise fee $ 10,000,000              
Termination period upon written notice 90 days              
Collaboration revenue     79,000 4,833,000 1,076,000 13,949,000    
Deferred revenue, current     7,267,000   7,267,000   $ 8,343,000  
Dermelix License Agreement | Collaboration Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Non-refundable upfront payment received for research agreement   $ 1,000,000            
Collaboration revenue     $ 0 $ 14,000 $ 0 $ 81,000    
Collaboration development expenses   $ 1,000,000            
Deferred revenue               $ 0
Development and Commercialization License | AbbVie Collaboration | Collaboration Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Collaboration option exercise fee $ 15,000,000              
Maximum | AbbVie Collaboration | Collaboration Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Development milestone payment 55,000,000              
Product approval and launch milestone payment 132,500,000              
Sales milestone payment $ 175,000,000